Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination

The distribution of the novel Covid-19 vaccines has been on a scale as unprecedented as the pandemic itself. While the vaccines promise to greatly reduce the spread and impact of the disease, encountering side-effects in clinical practice may pose diagnostic dilemmas. In this case report, we describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Aalberg, Jeffrey J, Collins, Timothy P, Dobrow, Ethan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194501/
https://www.ncbi.nlm.nih.gov/pubmed/34149984
http://dx.doi.org/10.1016/j.radcr.2021.05.031
_version_ 1783706423203463168
author Aalberg, Jeffrey J
Collins, Timothy P
Dobrow, Ethan M
author_facet Aalberg, Jeffrey J
Collins, Timothy P
Dobrow, Ethan M
author_sort Aalberg, Jeffrey J
collection PubMed
description The distribution of the novel Covid-19 vaccines has been on a scale as unprecedented as the pandemic itself. While the vaccines promise to greatly reduce the spread and impact of the disease, encountering side-effects in clinical practice may pose diagnostic dilemmas. In this case report, we describe a patient with known metastatic renal cell carcinoma who presents with axillary lymphadenopathy found on PET/CT imaging after receiving a Covid-19 vaccine, which was subsequently confirmed to be reactive lymphadenopathy following biopsy.
format Online
Article
Text
id pubmed-8194501
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81945012021-06-15 Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination Aalberg, Jeffrey J Collins, Timothy P Dobrow, Ethan M Radiol Case Rep Case Report The distribution of the novel Covid-19 vaccines has been on a scale as unprecedented as the pandemic itself. While the vaccines promise to greatly reduce the spread and impact of the disease, encountering side-effects in clinical practice may pose diagnostic dilemmas. In this case report, we describe a patient with known metastatic renal cell carcinoma who presents with axillary lymphadenopathy found on PET/CT imaging after receiving a Covid-19 vaccine, which was subsequently confirmed to be reactive lymphadenopathy following biopsy. Elsevier 2021-06-11 /pmc/articles/PMC8194501/ /pubmed/34149984 http://dx.doi.org/10.1016/j.radcr.2021.05.031 Text en © 2021 Published by Elsevier Inc. on behalf of University of Washington. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Aalberg, Jeffrey J
Collins, Timothy P
Dobrow, Ethan M
Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title_full Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title_fullStr Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title_full_unstemmed Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title_short Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
title_sort axillary lymphadenopathy in a renal cell carcinoma patient after covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194501/
https://www.ncbi.nlm.nih.gov/pubmed/34149984
http://dx.doi.org/10.1016/j.radcr.2021.05.031
work_keys_str_mv AT aalbergjeffreyj axillarylymphadenopathyinarenalcellcarcinomapatientaftercovid19vaccination
AT collinstimothyp axillarylymphadenopathyinarenalcellcarcinomapatientaftercovid19vaccination
AT dobrowethanm axillarylymphadenopathyinarenalcellcarcinomapatientaftercovid19vaccination